How to Use ISO 13485 Certificates for Overseas Registration of Medical Dressings

Key Summary

ISO 13485 certificates cannot be used directly as marketing authorization for overseas registration of medical dressings. They serve as foundational evidence that your quality management system meets international standards. To use it effectively, confirm your product's regulatory classification in the target country, then align technical documentation, local representation, and post-market obligations.

Most GHWP member countries and markets in Southeast Asia, the Middle East, and Latin America accept ISO 13485 as the basis for QMS audits, but technical files, performance verification, risk management, clinical evaluation, and biocompatibility testing often require localization or supplemental data. Labels and instructions for use must comply with the target country's language and regulations. A local agent or authorized representative is usually indispensable. Certificate control, change notification, and renewal obligations directly affect the validity of the registration certificate.

For Chinese medical device manufacturers, the safest approach is to first perform product classification and documentation gap assessment, then decide whether NMPA, CE, FDA, ISO 13485, or other market data can be reused. Target market registration typically affects technical files, authorized representatives, importer cooperation, label language, QMS certification, and subsequent change maintenance. If you proceed only by submitting documents, you risk deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends planning this issue within the framework of GHWP member countries and multi-country market access strategies, using one reusable core technical documentation set to support localization across different markets, rather than recreating files for each country.

Applicable Scenarios and Core Questions

Medical dressings include adhesive bandages, gauze, dressing patches, alginate dressings, hydrocolloid dressings, foam dressings, and similar products. After obtaining an ISO 13485 certificate, companies often mistakenly believe they can directly sell overseas with the certificate, or think a valid certificate is sufficient for registration. In reality, the ISO 13485 certificate is only proof of QMS conformity and cannot replace a product registration certificate or marketing authorization.

The core questions for overseas registration are: How does the target country define medical dressings? What risk classification applies? What technical evidence is required? Who submits the application? Is a local agent required? Regulatory logic varies significantly by country. For example, the US FDA classifies some dressings as Class I or II; under the EU MDR, most dressings are Class I or IIa; Southeast Asian and Middle Eastern countries may classify differently under the ASEAN Medical Device Directive or national regulations.

ISO 13485 is mainly used to demonstrate the manufacturer's system capability and build trust with regulators, but technical documentation, performance data, biocompatibility, and clinical evaluation still need to be prepared separately. Companies must understand the boundaries of the certificate's role and not treat it as a universal key to registration.

Registration Decision Logic

Step 1: Confirm whether the product falls under the target country's medical device regulatory scope. Some foam dressings, if used only as cosmetic patches or ordinary wound care products, may be excluded from medical device classification, but most dressings that claim to treat or promote healing remain medical devices.

Step 2: Determine the product's risk classification and registration pathway. Many non-invasive dressings that do not contact the wound directly are low-risk and may qualify for self-declaration or simplified registration. Dressings claimed for chronic wounds, with antimicrobial or bioactive components, carry higher risk and usually require full review and more stringent clinical evidence.

Step 3: Assess reusability of existing documents. If the company already holds an NMPA registration, CE certificate, or FDA 510(k), relevant technical files, QMS audit reports, sterilization validation, and biocompatibility data can be partially reused. The ISO 13485 certificate serves as QMS evidence, and MDSAP reports are persuasive in some countries.

Step 4: Confirm local agent and authorized representative requirements. Most non-local manufacturers must appoint a target-country agent responsible for communicating with regulators, receiving adverse event reports, and handling recalls. Companies should verify the agent's qualifications and agreement scope, and not simply have a nominal arrangement.

Step 5: Address post-market maintenance obligations. Registration certificates often have validity periods, requiring periodic renewal, change notifications, annual reports, or system re-audits. Maintaining the ISO 13485 certificate directly impacts the registration's continuation; if the system certificate is revoked, overseas registrations may also become invalid.

Documentation and Evidence

In addition to the ISO 13485 certificate, typical documentation for overseas registration includes:

• Product classification rationale
• Intended use statement
• Instructions for use and label samples
• Technical specification sheet
• Manufacturing process flowchart
• Raw material list
• Sterilization validation report (if applicable)
• Biocompatibility test report (ISO 10993 series)
• Stability data
• Clinical evaluation or literature evidence
• Risk management report (ISO 14971)

The ISO 13485 certificate mainly demonstrates that the QMS meets recognized standards, but it does not cover all evidence of product safety and performance. Regulators focus on whether the product is manufactured under a controlled system and whether every technical parameter is supported by validation data.

In multi-country registration, companies should build a core technical documentation library, treating product description, risk management, performance testing, biocompatibility, and clinical evidence as common modules, then localize for each target country. This includes language, units, local regulatory references, and special label requirements.

If the product contains drugs or bioactive components, additional drug or biological evaluation may be required. ISO 13485 cannot replace the review requirements for drug-device combination products. Companies should confirm early whether GMP certification or special production licenses are needed.

Common Mistakes

• Using the ISO 13485 certificate directly for advertising or as proof of marketing authorization, leading to rejection.
• Ignoring product classification and submitting all dressings as low-risk fast-track, only to be placed in full review.
• Directly translating existing technical files without adjusting intended use statements to target country regulations, causing disputes.
• Missing local agent requirements, failing to submit applicant or agent authorization letters, causing the registration process to stall.
• Over-relying on CE or FDA reports without verifying whether the target country accepts the test standards, version years, and laboratory qualifications behind those reports.
• Failing to establish a change notification mechanism, so changes in ISO 13485 scope are not updated in overseas registration files, leading to inconsistencies.
• Ignoring post-market surveillance plans, lacking adverse event reporting pathways and periodic risk updates, making certificate maintenance difficult.

Company Preparation Checklist

• Confirm the product's regulatory classification and registration pathway in the target country, using official databases or local agents if necessary.
• Organize ISO 13485 certificate, quality manual, and procedure documents, ensuring the certificate covers the product category and manufacturing site.
• Update product technical files, including performance specifications, test reports, raw material composition, sterilization and packaging validation.
• Prepare a risk management report and adjust risk acceptability criteria according to ISO 14971 or target country requirements.
• Complete biocompatibility evaluation, typically in line with ISO 10993 series, and confirm the testing laboratory's qualifications.
• Compile clinical evaluation or clinical evidence; high-risk dressings may require clinical literature or clinical trial data.
• Design labels and instructions for use in the target country's language and regulations, checking prohibited words and symbols in advance.
• Appoint a local agent and sign an agreement clearly defining the agent's responsibilities for adverse events, change applications, and registration renewals.
• Verify the ISO 13485 certificate's validity and audit cycle, ensuring continuous validity during the registration review.
• Establish a multi-country registration project management table to track submission dates, deficiency requirements, and validity periods, controlling resource investment.

AIMEILI Regulatory Interpretation and Business Impact

Companies most often misjudge the role of ISO 13485, viewing it as a registration qualification. In fact, the certificate is only the foundation of system compliance and cannot replace product registration. Early on, clarify the target market's classification and clinical evidence requirements, then decide on documentation gaps.

We recommend prioritizing the assembly of core technical documents, extracting reusable parts from ISO 13485, MDSAP, CE, or FDA files, such as QMS evidence, sterilization validation, and basic performance data. However, biocompatibility reports, labels, risk management, and clinical evaluation often need local adaptation, especially for different populations, regulations, and languages.

Local agent and certificate control are the most overlooked areas. Many companies appoint an agent only for administrative tasks without retaining control of registration files. If the agent changes or the agreement ends, the registration may become unreachable. Changes and renewals must also be managed systematically. Suspension or revocation of the ISO 13485 certificate directly threatens all overseas registrations that rely on it.

For multi-country registration, adopt a 'one core document package + multi-country localization' strategy to reduce duplicate work and deficiency risks. This requires complete basic product data, test reports acceptable to multiple countries, and a professional team managing submission timelines.

Common Follow-up Questions

Can ISO 13485 be used directly for US FDA registration?

No. The FDA requires manufacturers to establish a quality system per 21 CFR 820. ISO 13485 can be a reference but cannot replace FDA 510(k), premarket approval, or establishment registration. Technical submissions are still required under the FDA pathway, and FDA may conduct inspections.

What is the difference between the ISO 13485 certificate under CE marking and one used for overseas registration?

In CE marking, the ISO 13485 certificate is issued by a notified body after auditing and demonstrates system conformity with MDR requirements, but it is only part of the CE certification. In overseas registration, it can serve as system evidence, but not as product marketing authorization. Other countries' regulatory bodies may require additional audits or supplementary system documents.

If the ISO 13485 certificate does not cover a specific dressing, can it still be used for overseas registration?

Generally no. The certificate's scope must explicitly include the product's design, production, and related processes. If not, regulators will consider the system not effectively covering that product. Companies should contact their certification body to extend the scope before using it for registration.